OXiGENE news from FierceBiotech
NewsALSO NOTED: Ardana looks to sale or merger; Oxigene inks $40M capital deal; and much more...
> Edinburgh-based Ardana's CEO, says the biotech is looking for a sale or merger. Report > Oxigene has Read more...
ALSO NOTED: FDA to speed up generic approval; Genfit starts Phase II trials; and much more...
Could the steady trickle of generics approvals out of the FDA suddenly become a rapid stream? The agency is touting an initiative, called Generic Initiative for Value and Efficiency (GIVE), to speed Read more...
| Press ReleasesPRESS RELEASE: OXiGENE Reports Positive Interim Results from Phase Ib Zybrestat - Bevacizumab OXiGENE Reports Positive Interim Results from Phase Ib Zybrestat - Bevacizumab Combination Study in Advanced Solid Tumors WALTHAM, Mass. -- Oct 5, 2007 - OXiGENE, a clinical-stage, biopharmaceutical Read more... |
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets